CDK5 and Alzheimer disease: The expression levels of CDK5 and GRM2 were decreased in 5- and 10-month-old 5XFAD mice compared to the controls, providing a mechanistic basis for the synaptic dysfunction and cognitive impairment seen in AD (Fig. 4b, c).